title: Risk factors associated with bacteriological cure, new infection, and incidence of clinical mastitis after dry cow therapy with three different antibiotics.
abstract: Factors affecting bacteriological cure rates (BCR) and new intramammary infections (IMI) during the dry period as well as clinical mastitis (CM) during early lactation were investigated in 414 German Holstein dairy cows receiving dry cow therapy. Cows were treated with either benethamine benzylpenicillin (300,000 IU), penethamate hydriodide (100,000 IU), and framycetin sulphate (100 mg, n = 136), or cefquinome (150 mg, n = 135), or benzathine cloxacillin (1,280 mg, n = 143). Overall BCR, IMI, and CM at parturition were 86.4%, 20.7%, and 4.3%, respectively. The three antibiotic treatments differed only in BCR, with cloxacillin yielding better results than the others. Udder quarters from cows with > 4 lactations had a higher risk of IMI and CM at calving. Chronic changes in udder tissues were linked to a lower BCR and were associated with a higher risk of CM during early lactation. The risk of CM at calving was higher in udder quarters with unspecific or subclinical mastitis before drying off. In conclusion, with antibiotic dry cow therapy, age and health status of the udder appear to be major determinants of IMI and CM during the dry period and early lactation, while BCR was associated with the antibiotic type and udder tissue status.
authors: Production Medicine Unit, Clinic for Cattle, University of Veterinary Medicine Hannover, Bischofsholer Damm 15, D-30173 Hannover, Germany.
authors: Yasmin
authors: Y
authors: Gundelach
authors: Elke
authors: E
authors: Kalscheuer
authors: Henning
authors: H
authors: Hamann
authors: Martina
authors: M
authors: Hoedemaker
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary*; D002417:Cattle; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005601:Framycetin / Q000008:administration & dosage / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D015994:Incidence; D007774:Lactation; D008321:Mammary Glands, Animal / Q000382:microbiology* / Q000502:physiology; D008414:Mastitis, Bovine / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D005601:Framycetin; C068212:cefquinome